- 'Healthcare system in critical state' says company's Director - Africa Region
- Meetings held with Country's president and local companies
- Visit in wake of Cyclone Idai devastation
RAS AL KHAIMAH: Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has pledged its support to the Zimbabwean government to help boost the country's healthcare sector, days after a devastating tropical storm battered the country.
The announcement was made during a visit by the UAE pharmaceutical company to the African nation as part of a UAE delegation last month. Accompanied by representatives from Abu Dhabi Health Services Company (SEHA), the delegation toured Harare and met with Zimbabwe president, Emmerson Mnangagwa, as well as the country's Health and Childcare Minister, Obadiah Moyo.
Meetings were also held with representatives from local pharmaceutical companies NatPharm and CAPs during which Julphar made a commitment to support the local pharmaceutical market and offered to supply medicines and support local production. The trip took place just a week after Cyclone Idai made landfall in southern Africa – one of the most devastating storms to hit the continent in decades.
Zimbabwe's health delivery system has faced challenges in the past two decades, largely due to an economic crisis, and the country is in need of critical health services and medicines. Dr Jacques Safarian, Julphar's Director – Africa Region, said the company hoped to leverage its already strong presence in Africa by forging new relationships that added value and helped provide affordable healthcare solutions to families across Zimbabwe.
"Zimbabwe's healthcare system in a critical state and is in need of urgent support, especially with the supply of medicines," said Dr Safarian.
"As one of the largest pharmaceutical manufacturers in the region, we are already very active in Africa and we are well positioned to support the Zimbabwean government by providing access to lifesaving medicines at affordable prices. We see numerous opportunities in distribution and local production and hope to finalize agreements with NatPharm for importation and CAPs for local production very soon," he added.
-Ends-
About Julphar
Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa and for almost four decades, the company has been delivering high quality, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs more than 5,000 people and distributes pharmaceutical products to 50 countries on five continents.
Julphar's business is centered on three core business units – Julphar Diabetes Solutions, General Medicines and its consumer division, Julphar Life – which target major therapeutic segments including Gastrology, Pain Management, Wound Care, Antibiotics and Cardio-metabolism. Julphar has 16 internationally accredited facilities in Africa, Middle East and Asia that produce more than a million boxes of medicine a day. In 2012, Julphar became one of the largest producers of insulin in the world.
For more information, visit http://www.julphar.net
For media enquiries, please contact:
Chris Goward
Julphar
Corporate Communications
T +971-7-246-1461 | M +971-58-263-3997
Email: chris.goward@julphar.net
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
